---
title: "Innovent Says China NMPA Approves Jaypirca for Relapsed or Refractory CLL/SLL"
description: "Innovent Biologics Inc. announced that China's National Medical Products Administration has approved Jaypirca (pirtobrutinib) for adult patients with relapsed or refractory chronic lymphocytic leukemi"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277190001.md"
published_at: "2026-02-27T11:32:50.000Z"
---

# Innovent Says China NMPA Approves Jaypirca for Relapsed or Refractory CLL/SLL

> Innovent Biologics Inc. announced that China's National Medical Products Administration has approved Jaypirca (pirtobrutinib) for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, following at least one prior systemic therapy. The approval is based on the Phase 3 BRUIN CLL-321 trial results. Pirtobrutinib is developed by Eli Lilly and is commercialized in mainland China by Innovent.

Innovent Biologics Inc. said China’s National Medical Products Administration has approved Jaypirca (pirtobrutinib), a non-covalent BTK inhibitor, for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least one prior systemic therapy including a BTK inhibitor. The company said the approval was supported by results from the Phase 3 BRUIN CLL-321 trial comparing pirtobrutinib with investigator’s choice regimens. Innovent said pirtobrutinib is developed by Eli Lilly and Company and commercialized in mainland China by Innovent. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260227-12032576), on February 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [589720.CN - Guotai SSE STAR Brand Name Drug ETF](https://longbridge.com/en/quote/589720.CN.md)
- [513060.CN - Bosera Hang Seng Health Care ETF(QDII)](https://longbridge.com/en/quote/513060.CN.md)
- [588250.CN - Penghua SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588250.CN.md)
- [159316.CN - E Fund Hang Seng SCHK Innovative Drug ETF](https://longbridge.com/en/quote/159316.CN.md)
- [520880.CN - Hwabao WP Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520880.CN.md)
- [517110.CN - Guotai CSI Hugangshen Innovative Drugs Industry ETF](https://longbridge.com/en/quote/517110.CN.md)
- [513700.CN - Penghua CSI HK Connect Health Care Composite ETF](https://longbridge.com/en/quote/513700.CN.md)
- [513120.CN - GF CSI HK Innovative Drugs Industry ETF(QDII)](https://longbridge.com/en/quote/513120.CN.md)
- [516930.CN - Minsheng Royal CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516930.CN.md)
- [588860.CN - ICBCCS SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588860.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | [Link](https://longbridge.com/en/news/276822785.md) |
| Hangzhou Jiuyuan’s Semaglutide Biosimilar Jikeqin Advances Toward China Market Approval | Hangzhou Jiuyuan Gene Engineering Co Ltd has developed Jikeqin, a biosimilar of semaglutide for weight management. The d | [Link](https://longbridge.com/en/news/276936312.md) |
| CStone Wins Second UK Approval for Lung Cancer Drug Sugemalimab | CStone Pharmaceuticals has received UK approval for its lung cancer drug, sugemalimab, as a monotherapy for adult patien | [Link](https://longbridge.com/en/news/276549711.md) |
| China Medical System Gets China Acceptance for Atopic Dermatitis Drug | China Medical System Gets China Acceptance for Atopic Dermatitis Drug | [Link](https://longbridge.com/en/news/276718382.md) |
| Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | [Link](https://longbridge.com/en/news/276886600.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.